Pipeline

Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.

Pipeline

Pipeline Antigen Gene Basic research Preclinical Trial Clinical Trial Stage
Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial
BVAC-C HPV E6/E7 Recombination Gene

NCT Identifier : NCT02866006

  • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
  • Clinical Trial Stage : Phase-I Clinical Trial
  • Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-C
  • Clinical Trial Result : All dosages used during clinical trial were proven to be safe.

NCT Identifier : NCT02866006

  • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
  • Clinical Trial Stage : Phase-II Clinical Trial
  • Clinical Trial Purpose : Purpose of Clinical trial : To verify validity, safety, and tolerance either in single administration of BVAC or in joint administration of BVAC-C and chemotherapy.
  • Clinical Trial Result : In progress

NCT Identifier : TBD

  • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
  • Clinical Trial Stage : Phase-II Clinical Trial
  • Clinical Trial Purpose : Verification of validity, safety, and tolerance when administering BVAC-C with Immunosuppressants jointly.
  • Clinical Trial Result : To be scheduled
BVAC-B HER2/neu Recombination Gene

NCT Identifier : NCT03425773

  • Indication : HER2/neu positive/recurrent gastric cancer
  • Clinical Trial Stage : Phase-I Clinical Trial
  • Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-B
  • Clinical Trial Result : All dosages used during clinical trial were proven to be safe.
BVAC-P PAP / PSMA Fusion Recombination Gene
BVAC-M GP100 / MAGE-A3 Fusion Recombination Gene
BVAC-Neo Neo-Antigen

BVAC-C

BVAC-C uses HPV type 16/18’s carcinogen gene, E6/E7’s recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection.
CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.
Also, we are preparing for phase-II clinical trial to check co-administration effect with other medicines.

Publication
Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma : Safety, Clinical Activity, and Immunologic correlates
Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
10.3390/jcm9010147

BVAC-B

BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
BVAC-B completed phase-I clinical trial to check safety and drug tolerance and we are preparing for phase-II clinical trial.

BVAC-P

BVAC-P uses fusion cancer antigen of prostate acid phosphatase (PAP) and prostate-specific membrane antigen (PSMA) as antigen and applied on prostate cancer, renal cell cancer, and glioblastoma.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.

BVAC-M

BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.

BVAC-Neo

BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.

  • BVAC-C

    HPV E6/E7 Recombination Gene

    Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial

    NCT Identifier : NCT02866006

    • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
    • Clinical Trial Stage : Phase-I Clinical Trial
    • Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-C
    • Clinical Trial Result : All dosages used during clinical trial were proven to be safe.

    NCT Identifier : NCT02866006

    • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
    • Clinical Trial Stage : Phase-II Clinical Trial
    • Clinical Trial Purpose : Purpose of Clinical trial : To verify validity, safety, and tolerance either in single administration of BVAC or in joint administration of BVAC-C and chemotherapy.
    • Clinical Trial Result : In progress

    NCT Identifier : TBD

    • Indication : HPV type 16/18 Positive Progressive and Recurrent Cervical Cancer
    • Clinical Trial Stage : Phase-II Clinical Trial
    • Clinical Trial Purpose : Verification of validity, safety, and tolerance when administering BVAC-C with Immunosuppressants jointly.
    • Clinical Trial Result : To be scheduled

    BVAC-C

    BVAC-C uses HPV type 16/18’s carcinogen gene, E6/E7’s recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection.
    CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.
    Also, we are preparing for phase-II clinical trial to check co-administration effect with other medicines.

    Publication
    Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma : Safety, Clinical Activity, and Immunologic correlates
    Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285
    Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
    10.3390/jcm9010147

  • BVAC-B

    HER2/neu Recombination Gene

    Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial

    NCT Identifier : NCT03425773

    • Indication : HER2/neu positive/recurrent gastric cancer
    • Clinical Trial Stage : Phase-I Clinical Trial
    • Clinical Trial Purpose : Check on safety, drug-tolerance, maximum tolerance dose, and preliminary validation of BVAC-B
    • Clinical Trial Result : All dosages used during clinical trial were proven to be safe.

    BVAC-B

    BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
    BVAC-B completed phase-I clinical trial to check safety and drug tolerance and we are preparing for phase-II clinical trial.

  • BVAC-P

    PAP / PSMA Fusion Recombination Gene

    Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial

    BVAC-P

    BVAC-B uses recombination gene of human epidermal growth factor receptor 2 (Her2/neu) and applied on stomach cancer, breast cancer, and ovarian cancer.
    BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.

  • BVAC-M

    GP100 / MAGE-A3 Fusion Recombination Gene

    Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial

    BVAC-M

    BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
    While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
    BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.

  • BVAC-Neo

    Neo-Antigen

    Basic research Preclinical Trial Phase-I Clinical Trial Phase-II Clinical Trial Phase-III Clinical Trial

    BVAC-Neo

    BVAC-M uses fusion cancer antigen of GP100 and MAGE-A3 as antigen and melanoma is the main indication.
    While GP100 and MAGE-A3 couldn’t be developed as individual antigen, we introduced CeliVax and cancer antigen fusion technology for smooth non-clinical development.
    BVAC-P completed non-clinical development stage and we are preparing for phase-I clinical trial.